Surface Oncology, Inc.
https://www.surfaceoncology.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Surface Oncology, Inc.
China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey
After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.
GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.
Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule